FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2619002073> ?p ?o ?g. }

• W2619002073 endingPage "44280" @default.
• W2619002073 startingPage "44266" @default.
• W2619002073 abstract "// Andrea Bilger 1 , Julie Plowshay 2, 6 , Shidong Ma 1, 5 , Dhananjay Nawandar 3, 7 , Elizabeth A. Barlow 1 , James C. Romero-Masters 4 , Jillian A. Bristol 1 , Zhe Li 8 , Ming-Han Tsai 8 , Henri-Jacques Delecluse 8 and Shannon C. Kenney 1, 2 1 Department of Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA 2 Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA 3 Department Cellular and Molecular Biology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA 4 Department of Cellular and Molecular Pathology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA 5 Sanofi Pharmaceuticals, Cambridge, Massachusetts, USA 6 Rocky Mountain Infectious Disease Specialists, Aurora, Colorado, USA 7 Department of Cancer Biology and Immunology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA 8 Joint DKFZ Inserm Unit U1074, German Cancer Center (DKFZ), Heidelberg, Germany Correspondence to: Shannon C. Kenney, email: skenney@wisc.edu Keywords: therapy, lymphoma, lymphoproliferative disease, humanized mouse model, FDA-approved Received: March 17, 2017      Accepted: April 27, 2017      Published: May 15, 2017 ABSTRACT EBV infection causes mononucleosis and is associated with specific subsets of B cell lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly susceptible to EBV-induced lymphoproliferative disease (LPD), which can be fatal. Leflunomide (a drug used to treat rheumatoid arthritis) and its active metabolite teriflunomide (used to treat multiple sclerosis) inhibit de novo pyrimidine synthesis by targeting the cellular dihydroorotate dehydrogenase, thereby decreasing T cell proliferation. Leflunomide also inhibits the replication of cytomegalovirus and BK virus via both “on target” and “off target” mechanisms and is increasingly used to treat these viruses in organ transplant recipients. However, whether leflunomide/teriflunomide block EBV replication or inhibit EBV-mediated B cell transformation is currently unknown. We show that teriflunomide inhibits cellular proliferation, and promotes apoptosis, in EBV-transformed B cells in vitro at a clinically relevant dose. In addition, teriflunomide prevents the development of EBV-induced lymphomas in both a humanized mouse model and a xenograft model. Furthermore, teriflunomide inhibits lytic EBV infection in vitro both by preventing the initial steps of lytic viral reactivation, and by blocking lytic viral DNA replication. Leflunomide/teriflunomide might therefore be clinically useful for preventing EBV-induced LPD in patients who have high EBV loads yet require continued immunosuppression." @default.
• W2619002073 created "2017-06-05" @default.
• W2619002073 creator A5001676700 @default.
• W2619002073 creator A5006037079 @default.
• W2619002073 creator A5012636364 @default.
• W2619002073 creator A5012782074 @default.
• W2619002073 creator A5013916954 @default.
• W2619002073 creator A5015332170 @default.
• W2619002073 creator A5028943143 @default.
• W2619002073 creator A5042214841 @default.
• W2619002073 creator A5050586319 @default.
• W2619002073 creator A5074923818 @default.
• W2619002073 creator A5082636703 @default.
• W2619002073 date "2017-05-15" @default.
• W2619002073 modified "2023-10-14" @default.
• W2619002073 title "Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication" @default.
• W2619002073 cites W1547532383 @default.
• W2619002073 cites W1578954095 @default.
• W2619002073 cites W1963973972 @default.
• W2619002073 cites W1968923103 @default.
• W2619002073 cites W1976400658 @default.
• W2619002073 cites W1977809195 @default.
• W2619002073 cites W1981785841 @default.
• W2619002073 cites W1987512032 @default.
• W2619002073 cites W1994524871 @default.
• W2619002073 cites W2000614504 @default.
• W2619002073 cites W2008511202 @default.
• W2619002073 cites W2015616819 @default.
• W2619002073 cites W2019728262 @default.
• W2619002073 cites W2024991882 @default.
• W2619002073 cites W2026094543 @default.
• W2619002073 cites W2054213118 @default.
• W2619002073 cites W2055892558 @default.
• W2619002073 cites W2062816809 @default.
• W2619002073 cites W2071833051 @default.
• W2619002073 cites W2074479811 @default.
• W2619002073 cites W2075494258 @default.
• W2619002073 cites W2087638002 @default.
• W2619002073 cites W2092911406 @default.
• W2619002073 cites W2100870126 @default.
• W2619002073 cites W2107060734 @default.
• W2619002073 cites W2119423337 @default.
• W2619002073 cites W2126805876 @default.
• W2619002073 cites W2133247083 @default.
• W2619002073 cites W2138234417 @default.
• W2619002073 cites W2140058638 @default.
• W2619002073 cites W2146784451 @default.
• W2619002073 cites W2146853742 @default.
• W2619002073 cites W2148588361 @default.
• W2619002073 cites W2155610307 @default.
• W2619002073 cites W2160369223 @default.
• W2619002073 cites W2166043441 @default.
• W2619002073 cites W2221626926 @default.
• W2619002073 cites W2228301361 @default.
• W2619002073 cites W2285594441 @default.
• W2619002073 cites W2318894243 @default.
• W2619002073 cites W2401113962 @default.
• W2619002073 cites W2416873769 @default.
• W2619002073 cites W2467918292 @default.
• W2619002073 cites W2517490587 @default.
• W2619002073 cites W2520159331 @default.
• W2619002073 cites W2522939951 @default.
• W2619002073 cites W2529651453 @default.
• W2619002073 doi "https://doi.org/10.18632/oncotarget.17863" @default.
• W2619002073 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546479" @default.
• W2619002073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28574826" @default.
• W2619002073 hasPublicationYear "2017" @default.
• W2619002073 type Work @default.
• W2619002073 sameAs 2619002073 @default.
• W2619002073 citedByCount "60" @default.
• W2619002073 countsByYear W26190020732017 @default.
• W2619002073 countsByYear W26190020732018 @default.
• W2619002073 countsByYear W26190020732019 @default.
• W2619002073 countsByYear W26190020732020 @default.
• W2619002073 countsByYear W26190020732021 @default.
• W2619002073 countsByYear W26190020732022 @default.
• W2619002073 countsByYear W26190020732023 @default.
• W2619002073 crossrefType "journal-article" @default.
• W2619002073 hasAuthorship W2619002073A5001676700 @default.
• W2619002073 hasAuthorship W2619002073A5006037079 @default.
• W2619002073 hasAuthorship W2619002073A5012636364 @default.
• W2619002073 hasAuthorship W2619002073A5012782074 @default.
• W2619002073 hasAuthorship W2619002073A5013916954 @default.
• W2619002073 hasAuthorship W2619002073A5015332170 @default.
• W2619002073 hasAuthorship W2619002073A5028943143 @default.
• W2619002073 hasAuthorship W2619002073A5042214841 @default.
• W2619002073 hasAuthorship W2619002073A5050586319 @default.
• W2619002073 hasAuthorship W2619002073A5074923818 @default.
• W2619002073 hasAuthorship W2619002073A5082636703 @default.
• W2619002073 hasBestOaLocation W26190020731 @default.
• W2619002073 hasConcept C203014093 @default.
• W2619002073 hasConcept C2522874641 @default.
• W2619002073 hasConcept C2775905006 @default.
• W2619002073 hasConcept C2776036978 @default.
• W2619002073 hasConcept C2777575956 @default.
• W2619002073 hasConcept C2777703276 @default.
• W2619002073 hasConcept C2780640218 @default.
• W2619002073 hasConcept C2781375147 @default.

• next